News

Perrigo will acquire rights to the nicotine replacement therapies of both GSK and Novartis, NiQuitin and Nicotinell. Novartis’s cold sore management products in the EEA and cold and

Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government’s repository of critical medical supplies for biowarfare preparedness. Anthim has been developed under

Vitesse is a unique collaboration model initiated by Baxter Ventures to focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology.

The trial met its primary endpoint of time from randomization to first clinical fracture (HR=0.5, 95 percent CI 0.39-0.65, p<0.0001). The observed 50 percent reduction in fractures between

The drug development and license agreement between Transposagen and Janssen, which was announced in November of 2014, has been transferred to Poseida. The three-year drug development partnership and

Researchers from both the parties will initially focus on canine malignant melanoma, or skin cancer, and test Nuovo’s new anti-cancer peptide drug MMX for its ability to treat

These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1 in Chicago. Veliparib is an investigational oral poly (adenosine diphosphate

The companies will conduct clinical trials to evaluate the combination of Dynavax’s investigational toll-like receptor 9 (TLR9) agonist SD-101, with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) and its investigational

The Israeli company was first to file, making the product eligible for 180 days of market exclusivity. Risedronate sodium tablets, USP are the second approved product indicated to